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Α. ΠΕΡΙΛΗΨΗ  
Η  χρόνια λεμφοκυτταρική λευχαιμία (ΧΛΛ) ορίζεται ως μια κλωνική λεμφοϋπερπλαστική 
διαταραχή των Β- λεμφοκυττάρων . Η διαταραχή αυτή χαρακτηρίζεται από τη συσσώρευση 
λεμφοκυττάρων στο μυελό των οστών , στο περιφερικό αίμα αλλά και στους λεμφαδένες 
και τον σπλήνα. Πρόκειται για νόσο των μεγάλων ηλικιών ( συνήθης συχνότητα εμφάνισης  
μετά τα 70 έτη ) , με διπλάσιο επιπολασμό στο άρρεν φύλο , ενώ συγχρόνως αποτελεί τη 
συχνότερη μορφή λευχαιμίας στις χώρες του Δυτικού κόσμου. Σημαντικό βήμα στην 
θεραπευτική αντιμετώπιση της ΧΛΛ αποτέλεσε η χρήση των αναστολέων σηματοδοτικών 
οδών , των αντι- BCL2 και των αντι-CD20 αντισωμάτων. Πρόκειται για τα νέα θεραπευτικά 
χημειοφάρμακα ibrutinib, obinutuzumab, idelalisib, και venetoclax. Οι τυχαιοποιημένες 
ελεγχόμενες κλινικές δοκιμές (RCTs) αποτελούν το πιο αξιόπιστο μέσο για την αξιολόγηση 
της αποτελεσματικότητας των κλινικών παρεμβάσεων . Η μέθοδος CONSORT (Consolidated 
Standards of Reporting Tests) είναι μια προσέγγιση που βασίζεται στην τεκμηρίωση για τη 
βελτίωση της ποιότητα της υποβολής εκθέσεων σχετικά με τυχαιοποιημένες ελεγχόμενες 
κλινικές μελέτες. Σκοπός της παρούσας μελέτης είναι η αξιολόγηση της ποιότητας των 
δημοσιευμένων RCTs σχετικά με τη χρήση των ibrutinib, obinutuzumab, idelalisib, και 
venetoclax για τη θεραπεία της ΧΛΛ, σύμφωνα με τη λίστα CONSORT.  
Λέξεις κλειδιά: CONSORT, Τυχαιοποιημένες ελεγχόμενες κλινικές δοκιμές , Ibrutinib, 
Obinutuzumab, Idelalisib, Venetoclax, Χρόνια λεμφοκυτταρική λευχαιμία . 
Εισαγωγή: Οι τυχαία ελεγχόμενες κλινικές δοκιμές (RCTs) είναι το πιο αξιόπιστο εργαλείο 
για την αξιολόγηση της αποτελεσματικότητας των κλινικών παρεμβάσεων. Τα Ενοποιημένα 
Πρότυπα Δοκιμών Αναφοράς (CONSORT) είναι μια προσέγγιση που βασίζεται σε 
τεκμηρίωση για τη βελτίωση της ποιότητας των τυχαιοποιημένων ελεγχόμενων κλινικών 
δοκιμών. 
Στόχος: Η αξιολόγηση της ποιότητας αναφοράς των τυχαιοποιημένων ελεγχόμενων 
κλινικών δοκιμών που δημοσιεύτηκαν από το 2010 έως το 2018 και αναφέρονται σε 
ασθενείς με ΧΛΛ οι οποίοι έλαβαν ως θεραπεία οποιοδήποτε  από τα νεότερα φάρμακα 
χημειοθεραπείας-  ibrutinib, obinutuzumab, idelalisib και venetoclax - . Η αξιολόγηση έγινε 
χρησιμοποιώντας τη λίστα CONSORT. 
Μέθοδοι: Στο PubMed έγινε αναζήτηση τυχαιοποιημένων ελεγχόμενων κλινικών δοκιμών -
δημοσιευμένες στην αγγλική γλώσσα- που περιελάμβαναν ασθενείς με χρόνια 
λεμφοκυτταρική λευχαιμία οι οποίοι έλαβαν ως θεραπεία ένα από τα ακόλουθα φάρμακα 
ibrutinib, obinutuzumab, idelalisib και venetoclax. Οι δοκιμές θεωρήθηκαν επιλέξιμες όταν 
οι συμμετέχοντες είχαν εκχωρηθεί τυχαία σε τουλάχιστον δύο ομάδες θεραπείας. Η 
ποιότητα της αναφοράς αξιολογήθηκε με τη χρήση ερωτηματολογίου 25 θέσεων βάσει της 
λίστας ελέγχου CONSORT. Τα άρθρα ομαδοποιήθηκαν σε δύο χρονικές περιόδους (πριν και 
μετά το 2016) και στατιστικά συγκρίθηκαν για την πληρότητα των ερωτημάτων της λίστας 
CONSORT. 
Αποτελέσματα: Η αναζήτηση εντόπισε 18 κατάλληλα άρθρα για ανάλυση. Η πληρότητα των 
ερωτημάτων της δήλωσης CONSORT είναι μεγαλύτερη από το 75% σε 13 μόνο ερωτήματα 
από το σύνολο 37 που περιέχει τη λίστα. Σε 10 ερωτήματα το ποσοστό κάλυψης 
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ερωτημάτων είναι μικρότερο από 50%. Με την πάροδο του χρόνου, σημειώθηκε βελτίωση 
στη δομή καθώς και την  παρουσίαση των RCTs. 
Συμπεράσματα: Η ποιότητα της υποβολής RCTs με επίκεντρο τη χρόνια λεμφοκυτταρική 
λευχαιμία σε θεραπευόμενους που λαμβάνουν αναστολείς των σηματοδοτικών οδών,  
αντι–BCL2 ή αντι-CD20 , παρουσιάζει βελτίωση με την πάροδο του χρόνου  
εξακολουθώντας ωστόσο να παραμένει μη ικανοποιητική. Απαιτείται περαιτέρω βελτίωση 
της υποβολής εκθέσεων για την αξιολόγηση της εγκυρότητας της κλινικής έρευνας. 
 
 
ABSTRACT 
The definition of chronic lymphocytic leukemia (CLL) refers to a clonal lymphoproliferative 
disorder of B lymphocytes. This disorder is characterized by the accumulation of 
lymphocytes in the bone marrow, peripheral blood, but also in the lymph nodes and the 
spleen. This is a disease of the elderly (normal incidence after 70 years), with a double 
prevalence in male gender. While at the same time is the most common form of leukemia in 
the Western world. An important step in the treatment of CLL was the use of inhibitors of 
signal transduction pathways, anti-BCL 2 and anti-CD20 antibodies. These are the new 
therapeutic drugs ibrutinib, obinutuzumab, idelalisib, and venetoclax. Randomized 
controlled clinical trials (RCTs) are the most reliable tool for assessing the effectiveness of 
clinical interventions. The Consolidated Standards of Reporting Tests (CONSORT) is an 
approach based on documentation to improve the quality of reporting on randomized 
controlled clinical trials. The purpose of this study is to evaluate the quality of published 
RCTs regarding the use of ibrutinib, obinutuzumab, idelalisib, and venetoclax for the 
treatment of CLL, according to the CONSORT list. 
KEY WORDS : CONSORT, Randomized Controlled Trials, Quality, Ibrutinib, Obinutuzumab, 
Idelalisib, Venetoclax, Chronic Lymphocytic Leukemia, Methodology. 
 
 
Background: Randomized controlled clinical trials (RCTs) are the most reliable tool for 
assessing the effectiveness of clinical interventions. The Consolidated Standards of Reporting 
Tests (CONSORT) is an approach based on documentation to improve the quality of 
reporting on randomized controlled clinical trials. 
Objectives: Assess the reporting quality of RCTs for treatment for CLL ,in patients who 
received any of the new chemotherapy drugs-  ibrutinib, obinutuzumab, idelalisib, and 
venetoclax -  published from 2010 to 2018 using the CONSORT statement 
Methods:PubMed was searched for English-language RCTs involving patients with Chronic 
Lymphocytic Leukemia and who received one of the following drugs as a treatment- 
ibrutinib, obinutuzumab, idelalisib, and venetoclax-. Trials were considered eligible when 
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participants were randomly assigned to at least two treatment arms. Quality of reporting 
was assessed using a 25–item questionnaire based on the CONSORT checklist. The articles 
were grouped in two time periods  (before and after 2016) and statistically compared to the 
completeness of the CONSORT statement. 
Results: The search identified 18 eligible articles for analysis. Completeness of CONSORT 
statement questions grater than 75% occurs in 13 only queries from the total 37 that 
contains the list. In 10 queries the query coverage rate is less than 50%. Over time, there has 
been an improvement in the construction and presentation of RCTs. 
Conclusions: Quality of reporting in RCTs focusing on chronic lymphocytic leukemia and 
treatment with new TKIs is showing improvement over time, but still  remains 
unsatisfactory. Further improvement of reporting is necessary to assess the validity of 
clinical research.   
 
 
Β.INTRODUCTION  
With the advancement of technology, any new medical achievement is made available to 
any part of the world through its publication in world medical sites, providing a strong 
knowledge for every treating physician. The use of randomized clinical trials minimizes the 
bias in the efficacy of the therapeutic effects of each new drug. Randomized clinical trials 
have contributed to results free of bias[1,2,7,8]. In this way they contributed catalytically to 
improving the quality of therapeutic interventions, bringing more favorable results to 
patients. For these reasons, randomized studies have the highest placement among clinical 
trials [3,4,5,6]. 
However, a great deal of medical information and clinical studies are available in a number 
of online biomedical journals, many of which are not based on detailed descriptions. 
Important information about the design of the study, patient participation criteria, specimen 
randomization method and other clarification details are often bypassed and not 
mentioned. Ambiguities and inaccuracies generate concerns and questions to the reader 
[9,10,11]. 
In addition, it is known that most RCTs are conducted with funding from the pharmaceutical 
companies concerned. So we understand that information about industries and sources of 
finance is absolutely necessary. Thus eliminating suspicions of feasibility. 
 In order to limit bias in randomized clinical trials, the CONSORT statement  was published in 
1996 [12]. The use of the CONSORT list is related to improving the quality of RCTs. The 
revised CONSORT statement  consists of 25 questions which are classified into 6 categories. 
At the same time, a four-step flow chart is included. So we understand the use of the 
CONSORT statement as a guide for recording more complete and properly structured 
randomized clinical trials [13-17]. 
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This study evaluated the randomized clinical trials concerning the treatment of chronic 
lymphocytic leukemia using the novel inhibitors, anti-BCL2 and anti-cd20 antibodies [22-
25,33]. In the field of hematopoietic malignancies the evaluation of clinical trials is limited. 
We chose chronic lymphocytic leukemia and treatment with the newer drugs belonging to 
inhibitors of signal transduction pathways, anti-BCL2 and anti-cd20 antibodies [30-32] as the 
latter became more prevalent in the treatment of CLL [26-29]. So as their use becomes more 
and more extensive, the concerns about efficacy and side effects in real world data patients 
also increase. 
 
C. METHODS 
Data Sources, Search Strategies and Studies Selection 
PubMed was used as a data source. There was the search of randomized clinical trials 
involving the treatment of CLL in the period 2010-2018. In PubMed, we used as filters the 
‘‘Randomized Controlled Trial’’ type of article and ‘‘English’’ language. Then, as a search 
criterion we used the combination of the following terms: “Chronic lymphocytic leukemia”, 
“CLL”, “ibrutinib”, “obinutuzumab”, “idelalisib”, “venetoclax”, “inhibitors of signal 
transduction pathways”,  “tyrosine kinase inhibitors”, “anti-BCL2”  and “anti-CD20”. The 
trials were eligible if the participants were randomly assigned to at least two groups with a 
different treatment strategy for each group. At least one of the groups should be used as a 
therapeutic drug of the following: idelalisib, ibrutinib, venetoclax or obinutuzumab. 
 
Data Extraction and Reporting Assessment Tool 
As assessment tool for quality of reporting, we used the revised CONSORT checklist, which 
includes a 25-item questionnaire. CONSORT statement  includes 25-item checklist with sub-
items (total 37 items).  
We clarify that the criteria of the CONSORT statement in order to create a randomized 
clinical trial requires the randomization of patients into categories by randomization. 
Separation should be blinded and interventions similar in the groups of  patients . In 
addition, the criteria of the CONSORT list include the creator of the random distribution as 
well as the mechanism applied for random separation. Finally, reference is also made to the 
persons who recorded the results. 
 
Methodological Evaluation 
We  evaluated 18 randomized clinical trials associated with the treatment of CLL in  patients 
whoreceiving any of newer therapeutic drugs ibrutinib, obinutuzumab, idelalisib, and 
venetoclax. The tests took place over the period 2010-2018 which coincided with the 
development of novel inhibitors, anti-BCL2 and anti-CD20 antibodies. Data was imported 
into tables using the Microsoft Excel 2010 program. Unclear or alternative answers (except 
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yes or no) were recorded as negative responses. Only explicit references were included in 
the positive responses.  
The studies were divided into two categories depending on whether they were published 
before or after 2016. This chronological separation is due to the fact that the majority of 
studies related to novel inhibitors, anti-BCL2 and anti-CD20 have been published over the 
last two years. The purpose of this separation was to assess the quality and validity of the 
trials [18-20]. 
The SPSS statistical program was used and the two groups were compared according to the 
CONSORT statement. For the comparison of the two groups a chi-squared test was applied 
with the use of Weight Cases. The coverage ratios of the CONSPORT list queries were 
calculated for each time period according to the separation, as well as the overall rates for 
2010-2018. Also, the P value was calculated for each of the comparisons. (Table 1). 
 
 
D. RESULTS 
A total of 2631 potentially eligible references were identified (Fig. 1), of which 1579 were 
measured in the searching of another myeloid malignancy. 
Of the remaining 1052 articles, 1034 were rejected. The blockade is due to the fact that 692 
articles were not relevant to us. In particular, these were reported in other haematological 
malignancies such as lymphomas,  mantle lymphoma and B cell lymphoma. 340 articles were 
rejected as they showed non-randomized studies. Cohort studies as well as case control 
studies were included in this last category. In addition, two articles referring to experimental 
models in an animal population were excluded. 
So, finally, we ended up with 18 articles that were about our issue. These articles include 
randomized clinical trials and articles which describe randomized clinical trials. All of the 
material refers to the use of venetoclax, ibrutinib, idelalisib and obinutuzumab in the 
treatment of CLL patients. 
 
 
 
Main Results 
Of the 18 articles studied, 7 were published in the period 2010-2016 and 11 were between 
2017-2018. Table 1 shows the frequency of coverage of the CONSORT list queries in both the 
overall study period and sub-categories. The 37 queries in the list include questions about 
the title of each article, for example, if the study characterized randomized or not. 
References are then made to the scientific background of the study and to the methods 
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applied to carry out a randomized trial (randomization method, blinded sample, statistical 
methods). To control the effectiveness of the study, questions are included about the 
number of participants, their characteristics, course or discontinuation of the study, and the 
outcomes for each group. Finally, there is discussion on the interpretation and generality of 
the results, while information on sources of funding and registration protocols is also 
provided. 
In our study of questions such as Scientific background and explanation of rationale, Specific 
objectives or hypotheses and Generalisability, we observe full coverage in all studies Higher 
occupancy rates of 83% to 94% are presented in questions such as : 3a. Description of trial 
design (such as parallel, factorial) including allocation ratio, 4a. Eligibility criteria for 
participants, 4b. Settings and locations where the data were collected, 5. The interventions 
for each group with sufficient details to allow replication, including how and when they were 
actually administered, 13a. For each group, the numbers of participants who were randomly 
assigned, received intended treatment, and were analysed for the primary outcome, 18. 
Results of any other analyses performed, including subgroup analyses and adjusted analyses, 
distinguishing pre-specified from exploratory, 19. All important harms or unintended effects 
in each group (for specific guidance see CONSORT for harms) and 25.Sources of funding and 
other support (such as supply of drugs), role of funders. 
Percentages ranging from 50% to 77% are observed in queries about sample size (7a, 7b), 
type of randomization (8b), (11b), additional analyzes (12b), losses and exclusions of each 
group (13b), dates (14a), estimated numbers and outcomes (16,17a, 17b), interpretations - 
entries and protocols (22,23,24). 
Percentages smaller than 50% are observed in questions about the presentation of a 
structured study summary (1b), references to changes in methods and outcomes (3b, 6b), 
references to the method and how to create random distribution (8a, 10), early termination 
of the study (14b) and presentation of a table with the characteristics of the participants 
(15). These questions are covered at rates 27% to 44%. 
The smallest percentages are observed in the questions about the concealment mechanism 
of the distribution (9) and the determination of the blind (11a). Rates are 16% and only 11% 
respectively. 
 
 
Period Effect 
By comparing the two time periods we set (according to the results of Table 1), there is a 
significant improvement in 6 thematic sections of the CONSORT statement. The most 
important improvement is observed in the 24th query, which refers to the study protocol 
with  p value equal to 0.001. A significant improvement is also noted in the questions about 
the method of random distribution of the participants (8a), the statistical methods which 
used (12a) and the reports on termination or discontinuation of the study (14b). In these 
queries the p value equals 0.01. A final difference is also observed in questions 1b on the 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 17:33:52 EEST - 137.108.70.13
 7 
structured summary of study design (p value 0.02) as well as in question 23 concerning the 
entry in the test record (p value 0.06). 
 
DISCUSSION  
Our study in the field of randomized clinical trials in patients with CLL receiving any of the 
newer drugs - idelalisib, ibrutinib, venetoclax or obinutuzumab -  as a treatment reveals that 
essential thematic aspects of RCTs are often overlooked and not mentioned. These 
omissions often cause concerns to the reader, making it difficult for them to assess the 
validity of the results.  
Over the course of time, and especially in the last two years, there has been a significant 
improvement in the structure of RCTs. Fields such as the summary of the design of the trial, 
the description of the randomization methods, the description of the statistical methods, 
and reports on the termination or discontinuation of the study are now more detailed and 
accurate. Significant progress is made in presenting information on the study protocol, 
which is now more emphasized. 
Similar studies performed to test RCTs reliability in hematological malignancies such as 
lymphomas [20], acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic 
syndromes [21] show unsatisfactory results to cover the queries of the CONSORT list. 
Here we have to mention the limitations of our own study. In our study we evaluated 
articles published in PubMed. This choice was made as PubMed is the most commonly used 
medical database. Medical databases such as Cochrane Collaboration, SCOPUS, Embase, 
Web of Science, Clinical Trials and Clinical Trials Registry have not been studied. In addition, 
English was used as a language, and only articles in English were studied, which may 
contribute to bias. 
In conclusion, our results for RCTs in CLL patients receiving idelalisib, ibrutinib, venetoclax or 
obinutuzumab show that RCTs do not fully conform to the CONSORT statement 
guidelines.We often see information being skipped while questions of the CONSORT 
statemelt remain unanswered. However, over time, there has been an improvement in the 
structure and presentation of RCTs. We hope they will become even more credible in order 
to eliminate any concerns about the reliability and validity of the results in the future 
 
Abbreviations and Acronyms 
CLL Chronic lymphocytic leukemia 
RCTs Randomized Controlled Trial 
CONSORT Consolidated Standards of Reporting Trials 
SPSS Statistical Package for the Social Sciences 
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Table 1. 
Data items Combined  
2010-2018 
(n=18) 
Combined  
2010-2016 (n=7) 
Combined  
2017-2018 
(n=11) 
P  value 
ABSTRACT / TITLE     
1a 0.16 0.00 0.27 0.13 
1b 0.44 0.00 0.72 0.02 
INTRODUCTION     
2a 1.00 1.00 1.00 - 
2b 1.00 1.00 1.00 - 
METHODS     
3a 0.88 0.85 0,90 0.73 
3b 0.33 0.14 0,45 0.17 
4a 0.88 0.85 0,90 0.73 
4b 0.94 0.85 1,00 0.19 
5 0.83 0.71 0,90 0.28 
6a 0.66 0.71 0,63 0.73 
6b 0.27 0.00 0,36 0.07 
7a 0.50 0.42 0,54 0.62 
7b 0.77 0.71 0,81 0.60 
8a 0.33 0.00 0,54 0.01 
8b 0.61 0.42 0,72 0.20 
9 0.16 0.00 0,27 0.13 
10 0.38 0,14 0,54 0.08 
11a 0.11 0.00 0,18 0.23 
11b  0.61 0,57 0,63 0.78 
12a 0.50 0,14 0,72 0.01 
12b 0.61 0,42 0,72 0.20 
RESULTS     
13a 0.83 0.71 0,90 0.28 
13b 0.61 0.42 0,72 0.20 
14a 0.77 0.71 0,81 0.60 
14b 0.33 0.00 0,54 0.01 
15 0.33 0,28 0,36 0.73 
16 0.55 0,28 0,72 0.06 
17a 0.72 0,71 0,72 0.95 
17b 0.72 0,71 0,72 0.95 
18 0,83 0,71 0,90 0.28 
19 0,88 1,00 0,81 0.23 
DISCUSSION     
20 0,66 0,71 0,63 0.73 
21 1,00 1,00 1,00 - 
22 0,55 1,00 0,90 0.41 
OTHER 
INFORMATION 
    
23 0.55 0,28 0,72 0.06 
24 0.61 0,14 0,90 0.001 
25 0.83 0,71 0,90 0.28 
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Figure 1. 
                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References identified in Pub med : 
Venetoclax: n= 449 
Ibrutinib: n=1370                                   Total papers n = 2631 
Idelalisib: n= 478 
Obinutuzumab: n= 334 
 
 
Measured papers in another myeloid malignancy: 
Venetoclax : n= 285 
Ibrutinib: n= 875                               Total n= 1579 
Idelalisib: n= 246 
Obinutuzumab: n= 173 
Screened for eligibility: n=1052 
(venetoclax: n= 164, ibrutinib : n= 495, idelalisib: n= 232, obinutuzumab: n=161) 
Excluded : n= 1034 
 
Not relevant to topic: n=692 
Nonrandomized trials: n=340 
Αnimal experiments : n =2 
References retrieved as full text and included  
in final analysis:  n= 18 
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